# Reasoning — AstraZeneca UK Ltd. v. Atchley, No. 26-245 (CVSG moment)

**P(any grant) = 0.44; modal call: denied (narrowly).**

## What the record shows
Snapshot `2026-11-09.json` (forward mode, cutoff 2026-11-10). Paid petition docketed
Aug 26, 2026, from the D.C. Circuit's January 23, 2026 decision on remand (rehearing en banc denied
April 23, 2026, no dissent noted per `lower-court-docket.txt`). BIO Oct 7, reply Oct 21,
distributed for the Nov 6 conference (one distribution). On Nov 9 the Court invited the
Solicitor General's views. Two amicus filings for petitioners (U.S. Chamber; Charity & Security
Network, whose leave motion was granted Nov 9). Counsel: Lisa Blatt for petitioners; the BIO
is from the plaintiffs' side (the D.C. Circuit argument was by Kellogg Hansen counsel).

I read `questions-presented.txt`, and skimmed the parts of `petition.txt`, `brief-in-opposition.txt`,
`cert-reply.txt` and `decision-below.txt` that matter (it is the D.C. Circuit's own on-remand opinion, matching
the petition's description; panel Pillard and Wilkins with a third judge).

## Anchor
`context.json` band `high` (sal-v8), `cert_anchor.rate` = 0.348 (reached rate, 10 prior Terms).
The statpack's CVSG cut (paid scored segment) agrees: of 164 resolved CVSG petitions, 29.3% were granted and 5.5% GVR'd,
so the grant family is about 35%. I start from 0.35.

## Adjustments
Up:
- **Second trip.** This is the case's second time here. In No. 23-9 the Court called for the SG's views, the
  United States recommended a GVR in light of *Twitter v. Taamneh* and criticized the D.C. Circuit's
  nexus and culpability analysis, and the Court GVR'd. On remand the D.C. Circuit reinstated its holdings
  in substance. A lower court that appears to adhere to its prior view after a GVR draws attention, and
  the Court's second CVSG, rather than a quick denial, suggests some interest.
- **Claimed split** with the Second Circuit (*Ashley v. Deutsche Bank*, 144 F.4th 420 (2025)) on
  undifferentiated aid and culpability under *Taamneh*, and on proximate cause with the 2d/7th Circuits
  (*Rothstein*, *Kemper*). Those two circuits hear most ATA cases, and the petition argues the
  ATA's venue rules let plaintiffs pick the D.C. Circuit.
- Elite counsel, Chamber amicus, very large exposure (21 companies, six years of attacks).

Down:
- **Interlocutory, motion-to-dismiss posture.** Discovery is underway and issues were remanded. The BIO
  leans on that and cites statements respecting denial by Kavanaugh, Roberts and Alito.
- The BIO's argument that *Ashley* is a fact-bound application on weaker allegations is plausible, and the Court
  just set the *Taamneh* framework. The SG could well say that the lower courts should keep applying it.
- **The SG's view is uncertain.** The prior recommendation came from the previous administration. The current
  administration has sided with terrorism victims elsewhere (e.g., *Fuld*). Against that, the
  government's interest in not chilling contractors who supplied Iraq reconstruction at U.S. request
  points toward petitioners. I treat the recommendation as roughly a coin flip leaning grant/GVR, and the Court
  usually follows it.

Net: about 0.44. That is above the CVSG base rate but still below even, so my binary call is denial. I am near the line
and would not be surprised by a grant.

## Claims
- relist-increment 0.95: after a CVSG the petition is redistributed once the SG's brief is filed (likely
  May 2027). Only withdrawal or settlement prevents it.
- cvsg-increment 0.02: vacuous, since the CVSG is already on the docket. The harness masks it.
- summary-disposition-route 0.10: a grant is overwhelmingly likely to be plenary. A second GVR would only
  be possible after an intervening ATA decision, and a summary reversal on a pleading-stage record is unlikely.
- dissent-from-denial 0.12: a denial would most likely follow an SG recommendation to deny on interlocutory
  grounds, and in that case the Justices rarely write. A statement by Kavanaugh or Alito noting the issue for after final
  judgment is the most plausible writing.

## Caveats
I did not read the SG's prior brief directly. Its content comes from the petition's account of it. Corpus queries added
nothing case-specific: the docket-number lookup for 23-9 returned only usage text.
